drugset / Trial / NCT06649214

A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

NCT06649214

Phase 3 Not yet recruiting 654 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this \[clinical trial\] is to \[evaluate the safety and efficacy of olanzapine-samidorphan tablets\] in \[adults with schizophrenia\]. The main question\[s\] it aims to answer are: * \[question 1\] Olanzapine-samidorphan significantly mitigate weight gain better than olanzapine. * \[question 2\] Olanzapine- samidorphan and olanzapine have similar antipsychotic efficacy.

Timeline

Start
2024-11
Primary completion
2026-04
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olanzapine Small molecule 10 mg Oral
Comparator Olanzapine Small molecule 15 mg Oral
Comparator Olanzapine Small molecule 20 mg Oral
Subject Samidorphan Small molecule 10 mg Oral

Indications